Rockville, Maryland — September 23, 2026 — The global laser cancer therapy market is valued at USD 4.5 million in 2026 and is projected to reach USD 11.2 million by 2036, expanding at a 9.5% CAGR during the 2026–2036 forecast period, according to Fact.MR. The market reached USD 4.1 million in 2025. Demand is being supported by hospitals developing less-invasive local cancer treatment services, including laser-based procedures that can be performed on an outpatient basis in selected cases. The National Cancer Institute describes laser use in selected local cancer treatments and notes that some procedures can be performed on an outpatient basis.
Photodynamic therapy is another area supporting demand for laser systems and compatible fibres, probes and applicators. Fact.MR notes that light-activated treatments require illumination systems to match the photosensitizer and treatment site, creating demand for wavelength-specific platforms and controlled dose delivery. The report also points to clinical research such as the UK Health Research Authority’s SLITT-GBM study, which evaluates surgery combined with laser-induced thermal therapy for bilateral glioblastomas.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
Global Segment Leaders
- Product — Laser Therapy Systems: 42.6% share in 2026. These platforms establish treatment capability and determine which delivery accessories a hospital can use.
- Procedure Type — Minimally Invasive Surgery: 63.7% share in 2026. Endoscopic and image-guided access routes connect local laser energy delivery with specialist surgical workflows.
- Technology Setting — Integrated Surgical Systems: 55.2% share in 2026. Integration coordinates visualization, targeting and energy delivery within the treatment workflow.
- Distribution Channel — Direct Sales: 62.7% share in 2026. Capital-equipment purchases require configuration, commissioning, service and staff-training discussions between suppliers and hospitals.
- Pricing Tier — Mid Range Clinical Systems: 44.8% share in 2026. These systems provide defined treatment capabilities while allowing clinical departments to balance procedure requirements against capital budgets.
Country-Level Performance
| Country | CAGR | Key Growth Driver |
| Germany | 10.9% | Germany’s Federal Ministry of Health identifies improved oncology-care structures and stronger connections between services as priorities in the renewed National Cancer Plan. |
| Brazil | 10.0% | Brazil’s INCA provides 2026 esophageal-cancer incidence estimates by state, highlighting geographically uneven oncology demand and the role of referral hospitals. |
| USA | 9.0% | The National Cancer Institute describes laser applications in selected cancer and precancer treatments, including local ablation and photodynamic therapy. |
| UK | 8.1% | The UK Health Research Authority’s 2026 SLITT-GBM study evaluates surgery and laser-induced thermal therapy for bilateral glioblastomas. |
| Japan | 7.1% | PMDA documentation links the BioBlade Laser System with cetuximab sarotalocan for unresectable, locally advanced or recurrent head and neck cancer, creating an indication-specific drug-device pathway. |
Regional Context
Germany and Brazil form the faster-growing group among the five countries profiled, with CAGRs of 10.9% and 10.0%, respectively. Germany’s coordinated cancer-care structures provide specialist centres with a route to evaluate local-treatment technologies, while Brazil’s geographically uneven cancer burden increases the importance of referral hospitals, technical support and reliable accessory supply.
The USA, UK and Japan have projected CAGRs of 9.0%, 8.1% and 7.1%, respectively. U.S. demand is linked to established local-treatment pathways and specialist teams; UK adoption is being evaluated through research-led programmes; and Japan’s demand is shaped by tightly specified drug-device treatment pathways and regulatory indications.
The full report covers Germany, Brazil, USA, UK and Japan, across the broader regions represented in Fact.MR’s country analysis. The report specifically lists these five countries as its covered markets.
Competitive Landscape
Key companies profiled by Fact.MR include Varian Oncology, Modulight Inc., LAP GmbH Laser Applikationen, MN Medical, Neusoft Medical Systems, Accuray, Shinva Medical Instrument, ViewRay Incorporated, and Reflexion Medical. Fact.MR distinguishes therapeutic laser providers from companies participating in the broader radiation-oncology equipment environment, noting that some profiled businesses supply positioning lasers or radiotherapy systems rather than therapeutic cancer lasers.
Modulight Inc. supplies therapeutic laser platforms, including the ML7710, which Fact.MR describes as a multichannel platform with configurable wavelengths, calibration functions and safety interfaces. ViewRay Systems, established in 2024 following the acquisition of ViewRay’s assets, supplies the MRIdian radiation-therapy system; the report treats this as a broader radiation-oncology reference rather than therapeutic-laser manufacturing.
The report also cites 2026 developments from the German Federal Ministry of Health, Brazil’s INCA and the UK Health Research Authority, alongside PMDA documentation concerning the BioBlade Laser System in Japan. These developments illustrate the importance of specialist oncology structures, clinical research and indication-specific regulatory pathways to equipment adoption.
Explore More Related Studies Published by Fact.MR Research
Color Correcting Glasses Market
About Fact.MR
Fact.MR is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, medical devices, and pharmaceuticals.
For more information on the full report, visit: Laser Cancer Therapy Market
